VNDA - Vanda reports positive Phase 3 data for motion sickness drug
2024-05-15 11:26:48 ET
More on Vanda Pharmaceuticals
- Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
- Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much
- Vanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46M
- Vanda Pharmaceuticals up 15% as Future Pak sweetens bid (updated)
- Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals